Neurizon Therapeutics Limited (ASX:NUZ)

Australia flag Australia · Delayed Price · Currency is AUD
0.0820
-0.0010 (-1.20%)
At close: Mar 6, 2026
-34.40%
Market Cap 57.29M
Revenue (ttm) 5.98M
Net Income (ttm) -14.85M
Shares Out 698.63M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 771,201
Average Volume 560,007
Open 0.0830
Previous Close 0.0830
Day's Range 0.0820 - 0.0830
52-Week Range 0.0790 - 0.1850
Beta 1.27
RSI 36.44
Earnings Date Feb 26, 2026

About Neurizon Therapeutics

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neur... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 4
Stock Exchange Australian Securities Exchange
Ticker Symbol NUZ
Full Company Profile

Financial Performance

In fiscal year 2025, Neurizon Therapeutics's revenue was 1.54 million, an increase of 82.70% compared to the previous year's 841,713. Losses were -16.59 million, 116.3% more than in 2024.

Financial Statements

News

There is no news available yet.